Chemed (NYSE:CHE) Given New $633.00 Price Target at Royal Bank of Canada

Chemed (NYSE:CHE) had its price target trimmed by Royal Bank of Canada from $697.00 to $633.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has an outperform rating on the stock.

Chemed Trading Up 1.6 %

Shares of CHE opened at $533.17 on Tuesday. The firm’s 50-day moving average is $583.68 and its two-hundred day moving average is $566.74. Chemed has a twelve month low of $523.33 and a twelve month high of $654.62. The firm has a market capitalization of $8.02 billion, a P/E ratio of 26.94, a PEG ratio of 2.16 and a beta of 0.46.

Chemed (NYSE:CHE) last issued its earnings results on Tuesday, October 29th. The company reported $5.64 earnings per share for the quarter, missing the consensus estimate of $5.76 by ($0.12). Chemed had a return on equity of 27.86% and a net margin of 12.69%. The company had revenue of $606.18 million for the quarter, compared to analyst estimates of $612.22 million. During the same quarter in the previous year, the company posted $5.32 earnings per share. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. Analysts predict that Chemed will post 22.41 EPS for the current year.

Insider Buying and Selling at Chemed

In other Chemed news, Director Andrea R. Lindell sold 831 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $571.51, for a total value of $474,924.81. Following the sale, the director now owns 5,725 shares of the company’s stock, valued at $3,271,894.75. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Chemed news, Director Andrea R. Lindell sold 831 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $571.51, for a total value of $474,924.81. Following the sale, the director now owns 5,725 shares of the company’s stock, valued at $3,271,894.75. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director George J. Walsh III sold 200 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $577.95, for a total transaction of $115,590.00. Following the completion of the sale, the director now directly owns 3,446 shares in the company, valued at $1,991,615.70. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,144 shares of company stock valued at $3,002,419 over the last quarter. Corporate insiders own 3.32% of the company’s stock.

Hedge Funds Weigh In On Chemed

Institutional investors and hedge funds have recently modified their holdings of the company. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Chemed during the first quarter valued at approximately $1,064,000. ProShare Advisors LLC lifted its stake in shares of Chemed by 6,288.9% during the first quarter. ProShare Advisors LLC now owns 50,600 shares of the company’s stock valued at $32,482,000 after buying an additional 49,808 shares during the period. Sei Investments Co. increased its position in Chemed by 4.5% during the first quarter. Sei Investments Co. now owns 41,336 shares of the company’s stock worth $26,535,000 after purchasing an additional 1,780 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in Chemed during the first quarter worth approximately $4,512,000. Finally, Quantbot Technologies LP increased its position in Chemed by 167.3% during the first quarter. Quantbot Technologies LP now owns 2,999 shares of the company’s stock worth $1,925,000 after purchasing an additional 1,877 shares during the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.